Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease

American Journal of Cardiology

Volumn 113, Issue 1, 2014, Pages 76-83

  Gotto, Antonio M ^a   Cannon, Christopher P ^b   Li, Xiujiang Susie ^c   Vaidya, Sanskruti ^c   Kher, Uma ^c   Brinton, Eliot A ^d   Davidson, Michael ^e   Moon, Jennifer E ^a   Shah, Sukrut ^c   Dansky, Hayes M ^c   Mitchel, Yale ^c   Barter, Philip ^f  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Utah Lipid Center and Utah Foundation for Biomedical Research   (United States)

^e RADIANT RESEARCH   (United States)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANACETRAPIB; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; CHLORIDE ION; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POTASSIUM BICARBONATE; POTASSIUM ION; SODIUM ION;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BICARBONATE BLOOD LEVEL; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHLORIDE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONCENTRATION RESPONSE; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

EID: 84890436361     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.08.041     Document Type: Article

References (11)

1. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
2. F. Taylor, M.D. Huffman, A.F. Macedo, T.H. Moore, M. Burke, G. Davey Smith, K. Ward, and S. Ebrahim Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 1 2011 CD004816
3. P. Barter, A.M. Gotto, J.C. LaRosa, J. Maroni, M. Szarek, S.M. Grundy, J.J. Kastelein, V. Bittner, J.C. Fruchart Treating to New Targets Investigators HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310
4. C.P. Cannon, S. Shah, H.M. Dansky, M. Davidson, E.A. Brinton, A.M. Gotto, M. Stepanavage, S.X. Liu, P. Gibbons, T.B. Ashraf, J. Zafarino, Y. Mitchel, P. Barter Determining the Efficacy and Tolerability Investigators Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
5. M. Davidson, S.X. Liu, P. Barter, E.A. Brinton, C.P. Cannon, A.M. Gotto Jr., E.T. Leary, S. Shah, M. Stepanavage, Y. Mitchel, and H.M. Dansky Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib J Lipid Res 54 2013 467 472
6. H.M. Dansky, D. Bloomfield, P. Gibbons, S. Liu, C.M. Sisk, D. Tribble, J.M. McKenney, T.W. Littlejohn III, and Y. Mitchel Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia Am Heart J 162 2011 708 716
7. C.P. Cannon, H.M. Dansky, M. Davidson, A.M. Gotto Jr., E.A. Brinton, A.L. Gould, M. Stepanavage, S.X. Liu, S. Shah, J. Rubino, P. Gibbons, A. Hermanowski-Vosatka, B. Binkowitz, Y. Mitchel, P. Barter DEFINE Investigators Design of the DEFINE trial: Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib Am Heart J 158 2009 513 519
8. R. Krishna, A.J. Bergman, B. Jin, M. Fallon, J. Cote, P. Van Hoydonck, T. Laethem, I.N. Gendrano III, K. Van Dyck, D. Hilliard, O. Laterza, K. Snyder, C. Chavez-Eng, R. Lutz, J. Chen, D.M. Bloomfield, M. De Smet, L.M. Van Bortel, M. Gutierrez, N. Al-Huniti, K. Dykstra, K.M. Gottesdiener, and J.A. Wagner Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Clin Pharmacol Ther 84 2008 679 683
9. R. Krishna, M.S. Anderson, A.J. Bergman, B. Jin, M. Fallon, J. Cote, K. Rosko, C. Chavez-Eng, R. Lutz, D.M. Bloomfield, M. Gutierrez, J. Doherty, F. Bieberdorf, J. Chodakewitz, K.M. Gottesdiener, and J.A. Wagner Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies Lancet 370 2007 1907 1914
10. D. Bloomfield, G.L. Carlson, A. Sapre, D. Tribble, J.M. McKenney, T.W. Littlejohn III, C.M. Sisk, Y. Mitchel, and R.C. Pasternak Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients Am Heart J 157 2009 352 360
11. T. Teramoto, M. Shirakawa, M. Kikuchi, M. Nakagomi, S. Tamura, H.K. Surks, C.M. Sisk, and H. Numaguchi Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia Atherosclerosis 230 2013 52 60